To evaluate opthalmological and dermatological safety of skin care products on repeated use by subject of varied eye conditions and varied skin conditions

SERY COSMETICS LLP0 个研究点目标入组 30 人开始时间: 待定最近更新: 2022年10月17日

试验速览

暂无简介。

•1. Subject is having valid proof of identity and age.
•2. Subject with skin photo type III to V.
•3. Skin is healthy (free of eczema, wounds, inflammatory scar).
•4. Healthy subjects (no infectious and evaluative pathology which could make the subject vulnerable and stop the study, no pathology which could interfere with the
•study, no symptom in the process of an exploratory check-up)
•5. Female Subjects in the age group of 18 to 55.
•6. Subjects representing varied skin types (representation of all 4 skin types Ã¢â?¬â?? Oily,
•Normal, Dry and combination)
•7. Subjects representing varied eye conditions (representation of Normal Condition,
•8. Sensitive Condition, and Contact Lens Users).
•9. Subject Habitual of applying makeup.
•10. Subject Habitual waterproof make up.
•11. Subjects ready to follow instructions during the study period.
•12. Subjects willing to come for regular follow up visits.

•1. Subject is either pregnant/ planning a pregnancy, or lactating.
•2. Subject having known history or present condition of allergic response to any
•cosmetic products (face/eye)/ known or suspected intolerance to cosmetic
•ingredients including fragrance.
•3. Subject having any eye infection or allergy/ extremely sensitive eye condition.
•4. Subject having any form of cutaneous disease which may Influence the study
•5.Previous history of atopy with regards to allergic reactions, irritation or intense
•discomfort feelings to topical-use products, cosmetics or medication.
•6. Any history of significant dermatological diseases or conditions or medical
•conditions.
•7. Presence of open sores, pimples, or cysts at the application site
•8. Subject having extremely sensitive eye condition.
•9. Subject having ocular problems (stye, chalazion, conjunctivitis).
•10. Subject having eye infection or allergy.
•11. Participation in another clinical study (including cosmetic/ drug studies) or studies
•with a similar application site, within 30 days of the screening visit.
•12. Any participant who, in the judgment of the Investigator, should not participate in

发起方

SERY COSMETICS LLP